A recognized leader in clinical trial research, Robarts Clinical Trials is well connected to science and discovery with our global network of IBD specialists and key opinion leaders.
Robarts Clinical Trials has a proven track record as a collaborative IBD drug development partner with full service capabilities that extend from Canada to the US, Europe and beyond.
Robarts Clinical Trials is actively working with more than 300 IBD sites across more than 20 countries in Europe and North America. Since pioneering our first central image management solution in 2007 we have collaborated with more than 1000 sites from Africa, Asia, Australia, Europe, North and South America. Our central image management solutions have been included in more than 20 studies across all phases of development and include the central review of endoscopy videos and histopathology for determination of eligibility, primary and secondary outcomes.
Over the course of its history, Robarts Clinical Trials has become synonymous with successful trials related to Inflammatory Bowel Disease (IBD), notably Crohn’s Disease (CD) and Ulcerative Colitis (UC).
At Robarts Clinical Trials we are proud of our history of reinvesting our profits to advance scientific research. In order to fulfill our mission to improve human health we are focused on improving clinical trial quality, accelerating development timelines, and reducing investigator and patient burden. By investing our profits back into research and development our organization aims to achieve this by designing, testing and teaching high value strategies for treating inflammatory bowel disease.
As the preeminent leader in IBD clinical study operations, Robarts Clinical Trials is fully connected to science and discovery with a far-reaching network of global experts. Our current scientific leadership is shared among a trio of highly respected international scientists and IBD opinion leaders:
Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada.
His postdoctoral training included residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario and the Crohn’s and Colitis Foundation of Canada (CCFC). He has authored over 150 articles and book chapters and has given over 700 invited presentations at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials at the Robarts Research Institute, University of Western Ontario. His research efforts focus on the design and implementation of randomized controlled trials of therapy for Inflammatory Bowel Disease. He has been the principal investigator on numerous large-scale randomized clinical trials.
Geert D’Haens graduated from medical school at the Katholieke Universiteirt Leuven, Belgium in 1987.
Professor D’Haens specialized in gastroenterology at the University of Chicago Hospitals, USA in 1992 and University Hospitals Leuven in 1993, having completed his internship in 1991. He was board certified in internal medicine in 1992 and gastroenterology in 1999. He defended his Doctoral Thesis in 1996. Currently Professor of Medicine and Gastroenterology at the Academic Medical Centre, University of Amsterdam, Netherlands, Professor D’Haens is a specialist gastroenterologist with a clinical interest in inflammatory bowel disease and gastrointestinal oncology. He has particular expertise in mucosal immunology, gastrointestinal endoscopy and immunosuppression related to IBD.
Professor D’Haens was elected to the International Organization for Inflammatory Bowel Disease (IOIBD) in 2003 and is Chairman of the Clinical Trials Task Force and is also a member of the IOIBD Executive Committee. Memberships of other societies includes a Fellowship of the American Gastroenterological Association (2006), the European Society for Gastrointestinal Endoscopy Research Committee, and the European Crohn’s and Colitis Organisation (ECCO). His experience and expertise is valued by medical publishers as a reviewer (journals including Gastroenterology, Am J Gastroenterol, Gut, Lancet and IBD) and by the pharmaceutical industry in his capacity as consultant.
Professor D’Haens is the recipient of several awards including the Silver medal for “inflammatory bowel disease" from World Congress on Gastroenterology, Vienna, 1998, one of the many conferences he has been involved in organizing. With over 170 peer reviewed scientific articles and 33 chapters in medical textbooks Professor D’Haens has an impressive publication record and is widely recognized as an expert in the area of digestive diseases.
William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California.
He completed a gastroenterology fellowship at the Mayo Clinic in Rochester, Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became Professor of Clinical Medicine at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. Dr. Sandborn has published over 427 peer reviewed articles including articles in the New England Journal of Medicine, the Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. His research interests are clinical trials and clinical pharmacology related to Inflammatory Bowel Disease. He is currently Chief of the Division of Gastroenterology and Director of UCSD IBD Center in the UC San Diego Health System.
Robarts Clinical Trials developed the world’s first 21CRF PART 11 compliant Central Image Management Solution for endoscopy.
Since 2007 our development of CIMS stands as a testament to our mission of conducting high quality, multi-centre randomized trials designed to assess issues of importance to human health. We’re proud of our commitment to science, and to advancing endoscopic screening and disease outcomes assessments for the benefit of Sponsors and patients with IBD.
CIMS Endoscopy is a proprietary system that recognizes the importance of endoscopic assessment in early drug development by facilitating a central review of complex medical images.
Designed as both a quality outcomes and screening tool for determining patient eligibility, CIMS Endoscopy is recognized by our academic and industry partners as the premium solution for eligibility and outcomes determination in Crohn’s and ulcerative colitis studies.
Building upon our expertise in the assessment of mucosal healing, Robarts Clinical Trials has partnered with leading laboratories to offer CIMS Histopathology, an integrated sample management / software / service solution that facilitates biopsy, processing, digitization and the secure sharing of images to facilitate central review and scoring.
PO Box 5015, 100 Perth Drive
London, Ontario, Canada, N6A 5K8
4350 Executive Drive, Suite 210
San Diego, California, USA 92121
Pietersbergweg 17, Trinity Building C
1105 BD Amsterdam, The Netherlands